Facial balancing enthusiasts understand the importance of the chin in achieving overall harmony. Now, there is a new FDA-approved solution available to address chin concerns. Galderma’s Restylane Lyft has received official clearance for enhancing the chin in adults with mild to moderate retrusion, offering injectors a non-surgical option to add structure to the lower face.
Clinical trials have shown significant improvements within three months, with results lasting up to a year. Both patients and investigators have expressed high satisfaction with the natural-looking definition and seamless transition from the chin to the jawline.
Restylane Lyft, already approved for the midface, smile lines, and hands, is recognized for its firm gel and supportive lift. With this new indication, the filler now plays a crucial role in refining the lower face, enhancing subtle projection to strengthen the profile and support jawline contour.
Bill Andriopoulos, Vice President of Medical Affairs at Galderma, stated in a press release, “This approval underscores our commitment to expanding our Injectable Aesthetics portfolio to cater to the diverse needs of patients. By broadening the applications of innovations like Restylane Lyft, we aim to provide aesthetic practitioners with enhanced flexibility and precision to achieve their patients’ unique aesthetic goals.”
This recent approval offers injectors an additional method to shape and define the chin without the need for surgery or downtime. With a growing interest in lower-face contouring, the demand for treatments that create a balanced, natural-looking profile shows no signs of slowing down.